Obalon Therapeutics Stock Forecast, Price & News

Obalon Therapeutics' stock was trading at $1.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OBLN shares have decreased by 15.4% and is now trading at $0.88.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Obalon Therapeutics.

Wall Street analysts have given Obalon Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Obalon Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Obalon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Obalon Therapeutics.

Obalon Therapeutics, Inc. (NASDAQ:OBLN) issued its quarterly earnings data on Friday, November, 6th. The company reported ($0.20) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.13. The company earned $0.04 million during the quarter. Obalon Therapeutics had a negative return on equity of 133.43% and a negative net margin of 694.12%.
View Obalon Therapeutics' earnings history.

Obalon Therapeutics's stock reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

Some companies that are related to Obalon Therapeutics include Avinger (AVGR), Aethlon Medical (AEMD), Ra Medical Systems (RMED), Neovasc (NVCN), INVO Bioscience (INVO), Hancock Jaffe Laboratories (HJLI), Interpace Biosciences (IDXG), InspireMD (NSPR), Biostage (BSTG), Meat-Tech 3D (MTTCF), InVivo Therapeutics (NVIV), InspireMD (NSPR), Lianluo Smart (LLIT), Dynatronics (DYNT) and Plus Therapeutics (PSTV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), OPKO Health (OPK), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX), Co-Diagnostics (CODX), NIO (NIO), Novavax (NVAX) and Onconova Therapeutics (ONTX).

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

Obalon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Morgan Stanley (9.01%). Company insiders that own Obalon Therapeutics stock include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Nooshin Hussainy and William J Plovanic.
View institutional ownership trends for Obalon Therapeutics.

OBLN stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley. Company insiders that have bought Obalon Therapeutics stock in the last two years include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Nooshin Hussainy, and William J Plovanic.
View insider buying and selling activity for Obalon Therapeutics.

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OBLN stock can currently be purchased for approximately $0.88.

Obalon Therapeutics has a market capitalization of $6.84 million and generates $3.28 million in revenue each year. Obalon Therapeutics employs 34 workers across the globe.

The official website for Obalon Therapeutics is www.obalon.com.

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]